Latest news with #BSAjaikumar
&w=3840&q=100)
Business Standard
24-05-2025
- Business
- Business Standard
HCG Q4 PAT drops 65% to ₹7.4 cr; acquires Orbitrap Astral from Thermo
Bengaluru-based HealthCare Global Enterprises (HCG) reported a 65 per cent decrease in consolidated profit after tax (PAT) to Rs 7.4 crore during the fourth quarter of the financial year ended March. HCG further announced the acquisition of the Orbitrap Astral Mass Spectrometer from Thermo Fisher Scientific. 'Looking ahead, we are making focused investments in next-generation capabilities, especially in early cancer detection and precision medicine. In line with our commitment to cutting-edge diagnostics and research, we are pleased to share that we are acquiring the Orbitrap Astral Mass Spectrometer from Thermo Fisher Scientific — one of the most advanced platforms globally for high-resolution mass spectrometry,' said BS Ajaikumar, executive chairman, HealthCare Global Enterprises. 'The acquisition will significantly enhance our molecular and proteomic profiling capabilities, enabling more precise disease characterisation and paving the way for next-generation biomarker discovery and targeted therapies,' said Ajaikumar. HCG reported operating income at Rs 585.1 crore in Q4FY25, up from Rs 494.6 crore in the same period last year. The company reported that revenues for HCG Onco Specialty Centres (excluding MGM) grew by a robust 16.7 per cent year-on-year in FY25. The quarter's earnings before interest, taxes, depreciation, and amortization (EBITDA) stood at Rs 107 crore, a growth of 14 per cent while maintaining a margin a margin of 18.3 per cent. For the company's established centers, EBITDA grew 15 per cent at Rs 115.4 crore, and emerging centers witnessed a Rs 7 crore increase from Rs 4.9 crore, year-on-year. 'Continuing our strategic focus on inorganic growth, we acquired MG Hospital in Vizag in FY25, further consolidating our presence and establishing HCG as the leading cancer care provider in that region. This acquisition marks our third in just 18 months, highlighting our consistent and focused approach to expansion,' said Raj Gore, CEO HealthCare Global Enterprises. HCG further emphasised its long-term commitment to building a robust academic and research foundation. Through fellowship programs and clinical research initiatives, the organisation aims to nurture the next generation of oncology leaders.
United News of India
24-05-2025
- Business
- United News of India
HCG posts Rs 5,851 million revenue in Q4 FY25
Bengaluru, May 24 (UNI) HealthCare Global Enterprises Ltd. (HCG), India's leading speciality healthcare provider focused on oncology and fertility, announced its unaudited financial results for the quarter and full year ended March 31, 2025. The company reported consolidated revenue of Rs 5,851 million for Q4 FY25, marking an 18% year-on-year growth from Rs 4,946 million in the corresponding quarter last year. For the full financial year 2025, HCG's revenue stood at Rs 22,228 million, reflecting a robust 16% growth over the previous year. EBITDA for Q4 FY25 was recorded at Rs 1,070 million, registering a 14% increase year-on-year, with margins at 18.3%. Profit After Tax (PAT) for the quarter was INR 74 million, down from Rs 213 million in Q4 FY24. Key operational highlights include a 3.5% rise in Average Revenue Per Operating Bed (ARPOB) to Rs 44,236, and an improvement in Average Occupancy Rate (AOR) to 67% from 63.2% in the previous year's quarter. The company also expanded its infrastructure by adding two Linear Accelerators (LINACs) at Vizag and Nagpur, and one PET CT facility in Africa. Dr BS Ajaikumar, Executive Chairman of HCG, said, "We have concluded another year of strong performance and meaningful progress. HCG continues to lead India's battle against cancer with a pan-India presence. We are investing in next-generation capabilities, including advanced molecular diagnostics and precision medicine. Our acquisition of the Orbitrap Astral Mass Spectrometer will significantly enhance our disease profiling and targeted therapy development." Raj Gore, CEO, added, "FY25 was a strong year operationally and financially. Excluding Milann centres, revenues grew by 17.4% to INR 21,651 million and Adjusted EBITDA increased 18.3% to Rs 3,913 million with margins of 18.1%. Our strategic acquisitions, including MG Hospital in Vizag, strengthen our regional presence and growth outlook. We remain confident about sustaining momentum into FY26.' HCG operates 22 comprehensive cancer centres across India and Africa and 7 fertility centres under the 'Milann' brand. UNI BDN RN
Time of India
25-04-2025
- Health
- Time of India
Chief Minister Bhupendra Patel inaugurates Gujarat's largest private cancer centre at HCG Aastha Cancer Centre, Ahmedabad
The new facility combines advanced technology, enhanced capacity, and holistic care, reaffirming HCG's commitment to accessible, world-class oncology in Gujarat In a noteworthy development for cancer care in Gujarat, Bhupendra Patel , the Chief Minister of Gujarat, inaugurated the expanded HCG Aastha Cancer Centre in its new premises opposite Bhagwat Vidyapith, Sola. Now the largest private comprehensive cancer care centre in the state, the inauguration was attended by HCG's senior leadership, Dr BS Ajaikumar, Raj Gore, Dr Bharat Gadhavi, and Sudharshan Bhamare, marking a significant leap forward in delivering accessible, world-class oncology care to the region. With increased capacity, next-generation technology, and a holistic care model, the upgraded facility reinforces HCG Aastha Cancer Centre Ahmedabad's commitment to delivering integrated, high-impact cancer treatment to patients across Gujarat and beyond. With a 217-bed capacity, a 140 per cent increase from its previous strength, the hospital is now equipped to handle significantly higher patient volumes with enhanced efficiency and personalised care. This includes 23 surgical ICU beds, 10 medical ICU beds, 23 daycare beds, 16 pre- and post-operative beds, and 6 Bone Marrow Transplant (BMT) units. This capacity boost will enable the hospital to manage a projected 30-40 per cent increase in patient footfall, translating to over 55,000 outpatient visits and 9,000 inpatient admissions annually. Backed by a multidisciplinary team of over 100 in-house doctors, the centre offers seamless, end-to-end care across surgical, medical, and radiation oncology, nuclear medicine, paediatric haemato-oncology, and advanced diagnostics. Speaking on the occasion, Bhupendra Patel, the Chief Minister of Gujarat, said, 'The launch of the HCG Aastha Cancer Centre in Ahmedabad is a significant step forward in making advanced cancer care more accessible. With its cutting-edge technology, the hospital provides excellent cancer treatment. The expertise of the hospital's highly experienced and dedicated team will significantly benefit the patients. I also applaud HCG for setting up a trust to support needy patients.' The Chief Minister highlighted the importance of healthy living, saying, 'Prime Minister Shri Narendra Modi has ensured the availability of comprehensive health initiatives—from yoga to Ayushman Bharat. Everyone should pay attention to their lifestyle to maintain good health.' Dr BS Ajaikumar, Executive Chairman, Healthcare Global Enterprises Limited, said, 'At HCG, our core philosophy has always been to deliver the right treatment the first time. We believe that quality cancer care should never be limited by geography. The expansion of HCG Aastha Cancer Centre in Ahmedabad is not merely an infrastructure milestone — it is a reaffirmation of our commitment to making advanced, evidence-based oncology accessible to every patient, no matter where they live. This centre brings together cutting-edge technology, organ-specific expertise, and a deeply compassionate care model, setting the benchmark for the future of cancer treatment. In this era of precision medicine, we are increasingly focused on leveraging genomics and proteomics to better understand tumour biology and guide personalised therapies. This approach enables us to improve outcomes, even in advanced and recurrent cases. With this facility, we strengthen our resolve to make high-quality cancer care more accessible, affordable, and outcome-driven — not just for Gujarat, but for all of India.' Raj Gore, CEO, Healthcare Global Enterprises Limited, added, 'The launch of the new premise with the upgraded facility at HCG Aastha Cancer Centre marks a strategic milestone in our ongoing mission to redefine cancer care in India. This facility not only reinforces our leadership in oncology but also aligns with our long-term vision to make world-class, technology and quality-driven cancer treatment more accessible. By integrating advanced modalities such as robotic-assisted surgeries with the expertise of our multidisciplinary teams, we aim to set new benchmarks in precision oncology and improve patient outcomes across the region.' Dr Bharat Gadhavi, Regional Director, HCG Group of Hospitals, Gujarat and Rajasthan , added, 'This state-of-the-art centre integrates cutting-edge clinical infrastructure, efficient processes, and a dedicated team to deliver more effective and personalised treatment. With this expansion, we are better equipped to offer patients the specialised care they need for improved outcomes. Since beginning its journey in Gujarat in 2007, HCG has established comprehensive cancer care facilities in Rajkot, Bhavnagar, and Vadodara. This new facility further strengthens our commitment to providing holistic cancer care under one roof, becoming a hub for managing complex and recurrent cases.' Sudharshan Bhamare, COO, HCG Astha Cancer Centre , Ahmedabad, added, 'This centre has been a conscious investment to meet the growing cancer care needs of Gujarat. From increasing bed strength to introducing specialised ICUs and surgical units, every aspect has been designed to handle more complex cases efficiently. This enhanced centre also enables us to reduce wait times, enhance patient comfort, and offer advanced treatments under one roof.' The centre continues to elevate its precision-led treatment approach through the integration of advanced technologies — including robotic surgery for GI, urological, and gynaecological cancers, Gujarat's first Tomo Therapy unit, and scalp cooling technology to help reduce chemotherapy-induced hair loss — a regional first. In addition to clinical upgrades, the expanded facility enhances its patient support ecosystem with services such as genetic counselling, multilingual international patient assistance, home and palliative care, and peer-led survivor support groups facilitated by the HCG Foundation and Ahmedabad Cancer Foundation. With this landmark expansion, HCG Aastha Cancer Centre, Ahmedabad, not only strengthens its leadership in oncology but also sets a new benchmark for patient-centric, compassionate innovation in cancer care for Gujarat and beyond. Disclaimer - The above content is non-editorial, and TIL hereby disclaims any and all warranties, expressed or implied, relating to it, and does not guarantee, vouch for or necessarily endorse any of the content. Stay informed with the latest business news, updates on bank holidays and public holidays . Master Value & Valuation with ET! Learn to invest smartly & decode financials. Limited seats at 33% off – Enroll now!
Yahoo
23-02-2025
- Business
- Yahoo
KKR Acquires Controlling Stake in Indian Healthcare Provider Healthcare Global Enterprises for $400 Million
KKR to be the largest and controlling shareholder MUMBAI, India, February 23, 2025--(BUSINESS WIRE)--KKR, a leading global investment firm, and Healthcare Global Enterprises (BSE: 539787; NSE: HCG; "HCG"), a leading healthcare organization in India, today announced the signing of definitive agreements with CVC, a leading global private markets manager, under which funds managed by KKR ("KKR") will become the largest shareholder in HCG and assume sole control of HCG's operations. Dr. BS Ajaikumar, Founder of HCG, will take on the role of Non-Executive Chairman and be focused on driving clinical, academic and research and development excellence. As part of the transaction, KKR will acquire up to 54% of equity in HCG from CVC Asia V at a purchase price of INR 445 per share. Pursuant to the Securities and Exchange Board of India's ("SEBI") Takeover Regulations, an open offer will be conducted by KKR to purchase additional equity shares in HCG from public shareholders. Upon completion of the transaction, KKR is expected to hold an equity stake of between 54-77%. Founded in 1989, HCG is one of India's largest oncology hospital chains. HCG operates 25 medical care centers across 19 cities with best-in-class infrastructure including 2,500 beds, nearly 100 operating theaters and 40 linear accelerator machines (LINACs). Akshay Tanna, Partner and Head of India Private Equity, KKR, said, "HCG is a pioneer in cancer care in India and has established itself as an important healthcare provider in the country for the past three decades. As healthcare continues to be a thematic focus for KKR in India, our investment in HCG will support the development of medical infrastructure and the delivery of critical oncology services and care to more patients in the country. We look forward to leveraging KKR's global healthcare expertise to strengthen HCG's offerings and working with Dr. BS Jaikumar to further enhance HCG's clinical excellence." Dr. BS Ajaikumar, Founder, HCG, said, "I want to thank CVC for their support through the years, helping the management to put HCG in the strong position it is in today. I am delighted to welcome KKR, with their investment and operational expertise in healthcare in India and globally, as a majority shareholder in HCG. Patient well-being and outcomes will always be a top priority for us at HCG, and in my new role as Non-Executive Chairman, I will focus on clinical aspects involving multi-disciplinary approach to cancer care, and research and development; and look forward to the journey of HCG where it continues to stay at the forefront of clinical excellence, research, and academics." Siddharth Patel, Managing Partner, CVC, said, "We are proud to have supported HCG's transformation at a critical juncture in time to build it into one of India's leading healthcare organizations and the delivery of high-quality care to many patients over the years." Amit Soni, Partner, CVC added, "Our partnership with Dr. Ajaikumar and the management team is a testimony to the ability to combine clinical and professional acumen to increase the reach of cancer care in India. We thank Dr. Ajai and the management for their unparalleled support and commitment to a common vision." KKR makes its investment from its Asia Fund IV. This transaction marks KKR's latest investment in India's healthcare space. Past investments in this sector have included Baby Memorial Hospital, a leading regional multi-specialty hospital chains in India; Healthium, a leading Indian medical devices company; Infinx, a tech-enabled healthcare revenue solutions provider; Max Healthcare, one of India's largest hospital networks; JB, a leading branded formulations pharmaceutical company in India and Gland Pharma, a leading Indian pure-play generic injectable pharmaceutical products company. The transaction is expected to close by the third quarter of 2025, subject to customary closing conditions and regulatory approvals. About HCG HealthCare Global Enterprises Ltd. (HCG), headquartered in Bengaluru, is one of the largest providers of cancer care in India. Through its network of 25 comprehensive cancer centers, HCG has brought advanced cancer care to the doorstep of millions of people. HCG's comprehensive cancer centers provide expertise and advanced technologies for the effective diagnosis and treatment of cancer under one roof. About KKR KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR's insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR's investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR's website at For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group's website at About CVC CVC is a leading global private markets manager with a network of 30 office locations throughout EMEA, the Americas, and Asia, with approximately €200 billion of assets under management. CVC has seven complementary strategies across private equity, secondaries, credit and infrastructure, for which CVC funds have secured commitments of approximately €249 billion from some of the world's leading pension funds and other institutional investors. Funds managed or advised by CVC's private equity strategy are invested in approximately 140 companies worldwide, which have combined annual sales of over €162 billion and employ over 580,000 people. For further information about CVC please visit: Follow us on LinkedIn. View source version on Contacts Media Inquiries For HCG Shipali S Poojaryshipali.p@ For KKR Wei Jun Ong+65 6922 For CVC Delna IraniAdfactors PR+91 22 6757 4444cvc@
